Antisense Therapeutics Limited (ATHJF)

Antisense Therapeutics Limited (ATHJF) Financial Statements


Antisense Therapeutics Limited Financial Overview

Antisense Therapeutics Limited's market cap is currently ―. The company's EPS TTM is $-0.01; its P/E ratio is -4.81; Antisense Therapeutics Limited is scheduled to report earnings on August 28, 2024, and the estimated EPS forecast is
gt;-0.01. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Jun 21Jun 20Jun 19Jun 18
Income Statement-
Total Revenue-----
Gross Profit-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsAU$ 19.23MAU$ 6.02MAU$ 4.06MAU$ 2.90MAU$ 4.30M
Total AssetsAU$ 22.44MAU$ 7.00MAU$ 5.35MAU$ 3.70MAU$ 4.80M
Total DebtAU$ 227.40KAU$ 306.85KAU$ 135.26KAU$ 0.00AU$ 0.00
Net DebtAU$ -19.01MAU$ -5.71MAU$ -3.92MAU$ -2.90MAU$ -4.30M
Total LiabilitiesAU$ 1.30MAU$ 1.27MAU$ 821.23KAU$ 888.84KAU$ 580.86K
Stockholders EquityAU$ 21.14MAU$ 5.73MAU$ 4.53MAU$ 2.81MAU$ 4.22M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in AUD

Antisense Therapeutics Limited Earnings and Revenue History

Antisense Therapeutics Limited Debt to Assets

Antisense Therapeutics Limited Cash Flow

Antisense Therapeutics Limited Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis